Evidence map›Paper›PMID 33778075›Full record

ArticleBioMed research international2021

Adrienn Kis, Noémi Dénes, Judit P Szabó, Viktória Arató, Lívia Beke, Orsolya Matolay, Kata Nóra Enyedi, Gábor Méhes, Gábor Mező, Péter Bai and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Synthesis ofPharmaceutics · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Adrienn KisDivision of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.
Noémi DénesDivision of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.
Judit P SzabóDivision of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.
Viktória AratóDivision of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.
Lívia BekeDepartment of Pathology, Faculty of Medicine, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.
Orsolya MatolayDepartment of Pathology, Faculty of Medicine, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.ORCID https://orcid.org/0000-0001-6873-3444
Kata Nóra EnyediEötvös Loránd University, Faculty of Science, Institute of Chemistry, Budapest, Hungary.
Gábor MéhesDepartment of Pathology, Faculty of Medicine, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.ORCID https://orcid.org/0000-0003-2503-7451
Gábor MezőEötvös Loránd University, Faculty of Science, Institute of Chemistry, Budapest, Hungary.
Péter BaiDepartment of Medical Chemistry, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.
István KertészDivision of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.
György TrencsényiDivision of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.ORCID https://orcid.org/0000-0001-6456-6212
University of Debrecen · HUEötvös Loránd University · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe aminopeptidase N (APN/CD13) receptor plays an important role in the neoangiogenic process and metastatic tumor cell invasion. Clinical and preclinical studies reported that bestatin and actinonin are cytotoxic to APN/CD13-positive tumors and metastases due to their APN/CD13-specific inhibitor properties. Our previous studies have already shown that MATERIALS AND

methodsThree days after the inoculation of HT1080 and B16-F10 cells, mice were treated with intraperitoneal injection of bestatin (15 mg/kg) or actinonin (5 mg/kg) for 7 days. On the 5

resultsControl-untreated HT1080 and B16-F10 tumors were clearly visualized by the APN/CD13-specific

conclusionThe bestatin treatment is suitable for suppressing the neoangiogenic process and APN/CD13 expression of experimental HT1080 and B16-F10 tumors; furthermore,

Indexed as

AcetatesCD13 AntigensGallium RadioisotopesHeterocyclic Compounds, 1-RingMelanoma, ExperimentalMolecular ImagingNeoplasm ProteinsOligopeptidesRadiopharmaceuticalsAnimalsHumansMaleMiceMice, SCID1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononaneAcetatesCD13 AntigensGallium RadioisotopesHeterocyclic Compounds, 1-RingNeoplasm ProteinsNGR peptideOligopeptidesRadiopharmaceuticals

Identifiers

PMID33778075
PMCPMC7972841
OpenAlexW3134813109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.